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OBJECTIVE — Studies have suggested that insulin resistance plays a role in cognitive im-
pairment in individuals with type 2 diabetes. We aimed to determine whether an improvement
in insulin resistance could explain cognitive performance variations over 36 weeks in older
individuals with mild cognitive impairment (MCI) and type 2 diabetes.
RESEARCH DESIGN AND METHODS — A total of 97 older individuals (mean  SD
age766years)whohadrecently(2months)startedanantidiabetestreatmentofmetformin
(500 mg twice a day) (n  30) or metformin (500 mg/day)rosiglitazone (4 mg/day) (n  32)
or diet (n  35) volunteered. The neuropsychological test battery consisted of the Mini-Mental
State Examination (MMSE), Rey Verbal Auditory Learning Test (RAVLT) total recall, and Trail
MakingTests(TMT-AandTMT-B)performedatbaselineandevery12weeksfor36weeksalong
with clinical testing.
RESULTS — At baseline, no signiﬁcant differences were found between groups in clinical or
neuropsychologicalparameters.MeanSDvaluesintheentirepopulationwereasfollows:A1C
7.5  0.5%, fasting plasma glucose (FPG) 8.6  1.3 mmol/l, fasting plasma insulin (FPI) 148 
74pmol/l,MMSE24.92.4,TMT-A61.642.0,TMT-B162.878.7,thedifferencebetween
TMT-B and TMT-A [DIFFBA] 101.2  58.1, and RAVLT 24.3  2.1. At follow-up, ANOVA
models tested changes in metabolic control parameters (FPI, FPG, and A1C). Such parameters
improved in the metformin and metformin/rosiglitazone groups (Ptrend  0.05 in both groups).
ANCOVA repeated models showed that results for the metformin/rosiglitazone group remained
stable for all neuropsychological tests, and results for the diet group remained stable for the
MMSE and TMT-A and declined for the TMT-B (Ptrend  0.024), executive efﬁciency (DIFFBA)
(Ptrend  0.026), and RAVLT memory test (Ptrend  0.011). Results for the metformin group
remainedstablefortheMMSEandTMTsbutdeclinedfortheRAVLT(Ptrend0.011).Withuse
of linear mixed-effects models, the interaction term, FPI  time, correlated with cognitive
stability on the RAVLT in the metformin/rosiglitazone group ( 1.899; P  0.009).
CONCLUSIONS — Rosiglitazone may protect against cognitive decline in older individuals
with type 2 diabetes and MCI.
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lder individuals with type 2 diabe-
tes have a signiﬁcantly higher risk
ofcognitivedecline,especiallymild
cognitive impairment (MCI) and demen-
tia (1–3). The mechanisms explaining the
association between type 2 diabetes and
cognitive decline are still under investiga-
tion. It has been shown that individuals
with type 2 diabetes who do not maintain
optimal glycemic control (i.e., occur-
rences of hyperglycemic ﬂuctuations) are
more likely to start manifesting deﬁcits in
memory and mental processing speed
functions (4). Interestingly, a decline in
hyperglycemic levels has been associated
with an improvement in cognitive func-
tion in older individuals with type 2 dia-
betes (4). Plasma glucose ﬂuctuations are
alsoconsideredtoberesponsibleforarise
in reactive oxygen species (5), and a pro-
oxidative effect of postprandial hypergly-
cemia may actively contribute to
inappropriate regulation of vascular tone,
leading to cognitive deﬁcits (6). Alter-
ations in the insulin signaling pathway
have also been suggested as possible con-
tributors to cognitive dysfunction, espe-
cially memory (7). Insulin receptors are
selectively found in the hippocampus,
and insulin modulates levels of important
neurotransmitters involved in activating
cognitive functions (7–9). Insulin resis-
tance has been shown to be an indepen-
dent determinant of lower cognitive
performance in older individuals (10).
Furthermore, impaired insulin response
during midlife is associated with an in-
crease risk of Alzheimer disease up to 35
years later (11). These ﬁndings strongly
suggest that abnormal insulin action has
deleterious effects on cognition.
A decline in insulin resistance may be
beneﬁcial to cognition in older individu-
als with normal glucose tolerance (NGT)
and MCI or Alzheimer disease (12). In
particular, short-term treatment with ros-
iglitazone was associated with an im-
provement in delayed memory and
selective attention tests in older individu-
als with NGT and MCI or early Alzheimer
disease (12). However, whether a rosigli-
tazone-mediated decline in insulin resis-
tancecouldbeadvantageousforcognitive
function in older individuals with both
type 2 diabetes and MCI is unknown.
Consideringthatsuchindividualshavean
extremely high risk of cognitive decline,
animprovementininsulinresistancemay
have a protective impact. To test this hy-
pothesis, we performed neuropsycholog-
ical tests at timely intervals in a group of
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poor metabolic control and MCI who had
recently started an add-on antidiabetes
agent, either metformin or rosiglitazone,
tometforminmonotherapythatwasinad-
equate for control. We also included in-
dividuals who had recently begun a
personalized diet program and had not
previously used oral antidiabetes agents.
RESEARCH DESIGN AND
METHODS— Ninety-seven older in-
dividuals (mean  SD age 76  6 years)
were selected from a group of 200 indi-
viduals with type 2 diabetes in poor met-
abolic control and MCI. We included
individuals who had recently (2
months) began a personalized diet pro-
gram or had added to their metformin-
based treatment of 500 mg/day an
additionaldoseof500mg/daymetformin
or an additional dose of 500 mg met-
formin plus 4 mg/day rosiglitazone (Fig.
1). Physicians from our university outpa-
tient ofﬁces were asked to refer older in-
dividuals with such conditions to our
division for further selection. At the
screening examination, participants un-
derwent instrumental and clinical exami-
nations to exclude the presence of severe
macro- and microangiopathy (13), coro-
nary heart disease, heart failure, severe
hypertension (13), cancer, chronic ob-
structive pulmonary disease, upper limb
paresis or paralysis, severe depression
(14), and/or dementia. Neuropsychologi-
cal testing was performed in those indi-
viduals with memory impairment at the
screeningvisittotestforMCI(Fig.1).The
diagnosis of MCI was achieved according
to published criteria (15) as follows:
memory complaint referred by the sub-
ject and/or a family member; cognitive
impairment in 1 domains (executive
function,memory,language,orvisuospa-
tial); normal functional activities; and not
having dementia. Our study sample con-
sisted of 97 older individuals with type 2
diabetes and MCI undergoing antidiabe-
tes treatment as follows: metformin (500
mg twice a day) (MF group) (n  30);
metformin (500 mg/day)rosiglitazone
(4 mg/day) (MF/Rosi group) (n  32);
andpersonalizeddiet(Dgroup)(n35).
Data collection started in February 2006
and was completed in October 2008. All
subjects gave their informed consent be-
fore participating in the study, which was
approved by the ethics committee of our
institution.
Each participant underwent an in-
person interview to assess general health
and function 3 weeks before beginning
the protocol. The study protocol con-
sisted of timely follow-up visits (n  4)
every 12 weeks for 36 weeks, which in-
cluded a complete physical examination
(including information on adherence to
their oral antidiabetes or diet program),
laboratory assessments, neuropsycholog-
ical testing, and an electrocardiogram. At
baseline and at the last follow-up visit, an
echocardiogram and a cardiac stress test
with a heart scan were performed.
Baseline blood pressure was recorded
with a standard mercury sphygmoma-
nometer on three occasions separated by
intervals of 2 min and the average of the
last two measures was used in the analy-
sis. BMI was calculated as weight in kilo-
grams divided by the square of height in
meters. Habitual physical activity was as-
sessedusingamodiﬁedversionoftheEu-
ropean Prospective Investigation into
Cancer and Nutrition (EPIC) physical ac-




Fasting plasma insulin (FPI) was deter-
mined by a commercial double-antibody,
solid-phase radioimmunoassay (intra-
assay coefﬁcient of variation 3.1  0.3%,
cross-reactivity vs. proinsulin  0.9%;
Sorin Biomedica, Milan Italy). Serum glu-
cose(fastingplasmaglucose[FPG]),A1C,
serum lipid, and serum lipoprotein were
quantiﬁedfromfreshsamplesdrawnafter
participants had been fasting for a least
12 h. Stable A1C levels were determined
in triplicate on ion-exchange microcol-
umns at constant 18°C. Commercial en-
zymatic tests were used for serum total
and HDL cholesterol and triglyceride de-
terminations (Roche Diagnostics, Mann-
heim, Germany). Serum LDL cholesterol
was calculated by the Friedewald
formula.
Neuropsychological assessment
The Mini Mental State Examination




by physicians who were unaware of the
study design.
The MMSE was assessed for global
cognitive function (17) and covers many
cognitiveskillswithscoresrangingfrom0
to 30. The Trail Making Test is a visuo-
motor speeded task that consists of two
parts: TMT-A and TMT-B. TMT-A, a vi-
sual scanning test, requires one to draw a
line connecting consecutive numbers
from 1 to 25. TMT-B adds cognitive ﬂex-
ibilitytoTMT-Aandrequiresonetodraw
a line connecting numbers and letters in
alternating sequence (17). The score is
given by the amount of time in seconds to
complete the task (17). Although time
to completion scores are typically used to
examine aspects of attention and execu-
tive function (17), the difference between
the two scores, TMT-B minus TMT-A
(DIFFBA), provides a measure of cogni-
tive efﬁciency (18). The RAVLT was used
tomeasureimmediatememoryspan(11).
The sum of the ﬁve presentations of the
immediate recall of a 15-word list was
used in analyses. Depression was evalu-
Figure 1—Patient recruitment ﬂow diagram. *Oral antidiabetes drug initiated within the last 2
months. §According to data of Petersen (2004)(15). aMCI, amnestic MCI.
Abbatecola and Associates
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(14).
Echocardiographic assessment
All participants underwent two-
dimensional echocardiography at base-
line and at the 36th week of follow-up
using echocardiographs with M-mode,
two-dimensional, and pulsed, continu-
ous-wave with color-ﬂow Doppler
capabilities.
Cardiac stress test with heart scan
Scintigraphicacquisitionwasmadeatrest
and during exercise. Stress consisted of
supine dynamic exercise on a bicycle er-
gometer, beginning with 25 W at 60 rpm
and increasing by 25-W steps over 2 min
until reaching the 75-W load. This work
was maintained for 4 min for the stress
scintigraphic scan. During exercise, elec-
trocardiogram standard recordings were
taken every 2 min. For radionuclide an-
giography, erythrocytes were labeled “in
vivo” with 25 mCi of
99mTc-pertechne-
tate. The studies were performed with a
small ﬁeld of view gamma camera (Basi-
CAM; Siemens, Erlangen, Germany)
equipped with a low-energy, general pur-
pose, parallel hole collimator. Energy dis-
crimination was provided by a 20%
window centered over the 140-keV pho-
topeak of
99mTc. Angioscintigraphic pa-
rameters were evaluated at rest and at
75 W.
Statistical analyses
Statistical analyses were performed using
SPSS (version 15.0; SPSS, Chicago, IL).
All data are presented as means  SD. To
approximate normal distributions, log-
transformed values for plasma triglycer-
ide and insulin were used in statistical
analyses and back-transformed for data
presentation. ANOVA was used to evalu-
ate the differences in clinical and meta-
bolic characteristics according to the
antidiabetes group. FPG, FPI, and A1C
were evaluated over time using ANOVA
within and between groups. Partial cor-
relations investigated the relationship
between two variables independently
of covariates. A repeated-measures
ANCOVA was created to determine the
change in cognitive performance within
each group over time after adjustment for
cofounders such as age, sex, years of ed-
ucation, BMI, diabetes duration, systolic
blood pressure physical activity, depres-
sion, A1C, FPG, and triglycerides. Partial
correlationswereperformedatbaselinein
the whole study group among cognitive
test scores (MMSE, TMT-A, TMT-B,
DIFFBA, and RAVLT) and FPI levels,
while adjusting for age, years of formal
education, diabetes duration, and treat-
ment group. To test the association be-
tween the variation of FPI on
neuropsychological testing, separate lin-
ear mixed-effects regression models were
created with cognitive performance tests
(MMSE, TMT-A, TMT-B, DIFFBA, and
RAVLT) as dependent variables after ad-
justment for the above covariates includ-
ing group, as ﬁxed effects in the entire
population. An interaction term of FPI 
time was also included to estimate the
change of FPI and change in cognitive





There were no signiﬁcant differences
found among clinical, biochemical, and
neuropsychological testing according to
antidiabetes group. Participants were
overweight (BMI 27.7  3.5 kg/m
2) with
poor control of the following metabolic
parameters: FPG 8.6  1.3 mmol/l, FPI
145.6  17.8 pmol/l, and A1C, 7.5 
0.5%. All subjects had good functional
status (activities of daily living 5.9  0.1
and instrumental activities of daily living
6.9  0.8) and were not depressed (Geri-
atric Depression Scale score 3.5  2.2).
Baseline clinical characteristics according
to antidiabetes group are reported in Ta-
ble 1.
At baseline, partial correlations were
performedbetweenmetaboliccontrolpa-
rameters (FPI, FPG, and A1C) and neuro-
psychologicaltestscores(MMSE,TMT-A,
TMT-B, DIFFBA, and RAVLT) in all par-
ticipants after controlling for age, years of
education, diabetes duration (years), and
antidiabetes group. We found that higher
FPI levels independently correlated with
worse RAVLT test scores (r  0.227;
P  0.029) and higher A1C levels corre-
lated with longer times of execution on
the TMT-B and the DIFFBA (r  0.212,
P  0.42; r  0.213, P  0.43, respec-
tively). There were no signiﬁcant correla-
tions found between FPG and any
neuropsychological test.
Follow-up
All participants (n  97) completed the
studyprotocolwithoutanyadverseeffect.
No participant experienced a cardiovas-
cular event. Participants adhered to their
antidiabetes program during the observa-
tion period.
Table 1—Baseline clinical characteristics according to antidiabetes group
All D group MF group
MF/Rosi
group
n 97 35 30 32
Age (years) 76  67 7  67 5  67 6  6
Sex (male/female) 53/44 18/17 17/13 18/14
Diabetes (years) 5.7  3.3 5.2  3.3 5.6  2.9 6.1  3.7
BMI (kg/m
2) 27.7  3.5 28.3  3.9 27.3  3.4 27.4  3.0
Waist-to-hip ratio 0.89  0.8 0.90  0.8 0.89  0.8 0.91  0.8
FPG (mmol/l) 8.44  1.11 8.44  1.22 8.28  0.94 8.5  0.89
FPI (pmol/l) 148  74 150  75 149  73 147  13
A1C (%) 7.5  0.5 7.5  0.4 7.4  0.6 7.5  0.4
Cholesterol (mmol/l) 5.68  0.83 5.71  0.75 5.68  0.85 5.63  0.93
LDL (mmol/l) 3.46  0.85 3.49  0.80 3.51  0.85 3.39  0.93
HDL (mmol/l) 1.01  0.28 1.03  0.31 1.01  0.28 0.98  0.26
Triglycerides (mmol/l) 2.55  0.58 2.56  0.7 2.48  0.56 2.60  0.45
Systolic blood pressure (mmHg) 150  21 150  19 147  18 153  24
Diastolic blood pressure (mmHg) 85  78 5  78 5  78 4  7
Ejection fraction (%) 52.7  2.9 53.9  2.5 52.4  2.2 51.7  3.2
Physical activity* 2.8  1.0 2.8  1.0 2.7  1.1 2.8  1.0
MMSE 24.0  2.5 22.9  2.1 24.1  2.3 24.0  3.0
TMT-A (s) 67.6  42.6 72.2  46.5 61.5  30.6 67.8  48.1
TMT-B (s) 161.1  63.7 158.7  60.0 172.7  61.8 162.5  76.8
DIFFBA (s) 101.2  58.1 111.6  60.1 95.0  44.9 98.2  68.1
RAVLT 24.5  2.3 24.8  2.5 24.7  2.2 24.0  2.1
Data are means  SD. *According to EPIC questionnaire (see RESEARCH DESIGN AND METHODS).
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and FPG was observed in those using oral
antidiabetes drugs, whereas those using a
personalized diet showed a signiﬁcant
worsening of these parameters (Ptrend 
0.05) (Fig. 2). Nevertheless, despite the
evidence that A1C showed a similar de-
cline in both groups using oral antidia-
betes agents, FPI levels signiﬁcantly
improved in the MF/Rosi group only
(Fig. 2).
Using separate ANOVA repeated
models, we found that the interaction
terms MMSE  group, TMT-A  group,
TMT-B  group, DIFFBA  group, and
RAVLT  group were all statistically sig-
niﬁcant (P  0.018, P  0.001, P 
0.001,P0.001,andP0.001,respec-
tively). The MMSE and the TMT-A did
not signiﬁcantly vary over time in any
group. However, TMTB and DIFFBA sig-
niﬁcantly worsened in the D group (P 
0.024 and P  0.026, respectively),
whereas there were no signiﬁcant varia-
tions over time in the MF or MF/Rosi
groups (data not shown). The RAVLT
memory score signiﬁcantly declined over
time in the D and MF groups (Ptrend 
0.011 and Ptrend  0.004, respectively),
whereas the MF/Rosi group did not show
any signiﬁcant variations over time (P 
0.414). In ANCOVA repeated models ad-
justed for age, sex, years of education,
BMI, diabetes duration, systolic blood
pressure, physical activity, depression,
A1C, FPG, and triglycerides, we found
that the following interaction terms,
MMSE  group, TMT-A  group, TMT-
B  group, DIFFBA  group, and
RAVLT  group were all statistically sig-
niﬁcant (P  0.017, P  0.001, P 
0.004, P  0.001, and P  0.001,
respectively).
A further analysis was used to test
whether the variation in FPI levels could
predict cognitive performance over time.
Considering that mean FPI levels in the
entire study sample were signiﬁcantly
lower compared with baseline values
(145.6  17.8 vs. 140.3  18.4; P 
0.05), we performed an initial regression
model in the entire study population, ad-
justing for multiple confounders. We
found that the interaction term, FPI 
time, independently predicted neuropsy-
chological test score variations in the
TMT-B and RAVLT only (Table 2). As re-
ported previously, the MF/Rosi group
also demonstrated a signiﬁcant decline in
FPI levels; therefore, the same analysis
was performed in the MF/Rosi group in
which FPI  time independently pre-
dicted variations in the RAVLT test only
(Table 2).
CONCLUSIONS— In older individ-
uals with type 2 diabetes and MCI, we
observed an improvement in metabolic
control parameters (A1C, FPG, and FPI)
in those using oral antidiabetes agents
metformin or metforminrosiglitazone
compared with those using a well-
controlled personalized diet over 36
weeks. We also found that a well-
controlled diet was associated with a sig-
niﬁcant decline in cognitive performance
on executive functioning and memory
tests, whereas monotherapy with met-
formin was associated with a decline in
memory performance. The MMSE and
Figure 2—Changes in A1C, cardiovascular PPG, and FPG over time according to antidiabetic
treatment. Œ, D group; E, MF/Rosi group; f, MF. *Ptrend  0.05 within the group over time.
PPG  postprandial glucose, FPG  fasting plasma glucose.
Abbatecola and Associates
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changes in over time, and this may be ex-
plained by the fact that such neuropsy-
chological tests do not show signiﬁcant
variations over a short observational pe-
riod compared with tests measuring cog-
nitive ﬂexibility, cognitive efﬁciency, and
memory (18). We found that the use of
metforminrosiglitazone was associated
with stable cognitive performance on all
neuropsychological tests over time. Our
ﬁndings suggest that an improvement in
circulating insulin levels may have a pro-
tective role against cognitive decline and
also suggest that additional use of insulin
sensitizers, like rosiglitazone, in older in-
dividuals with type 2 diabetes at a signif-
icantly higher risk of cognitive decline
may be beneﬁcial. Improvement in meta-
bolic and glycemic control has been
shown to be associated with a better cog-
nitiveperformancestatusonlyinolderin-
dividuals with type 2 diabetes and good
cognitive status (4,19). Furthermore, re-
ductionsinhyperglycemicfastingglucose
levels were accompanied by correspond-
ing improvements in cognition, whereas
signiﬁcant improvements in FPI levels
were not during a 24-week trial (4). In-
deed, our ﬁndings add further clariﬁca-
tion to the literature by demonstrating
that improvements in FPG were not asso-
ciated with changes in cognitive perfor-
mance, whereas the improvement in FPI
levels predicted cognitive change in older
individualswithtype2diabetesandMCI.
In particular, the MF/Rosi group demon-
strated a signiﬁcant decline in FPI, which
in turn, predicted changes in perfor-
mance on memory, the leading deﬁcit of
amnestic MCI. The metabolic and hemo-
dynamicproﬁleofdiabetes,includingco-
morbidities such as hypertension,
hyperinsulinemia, and obesity, modu-
latesvascularhealthandneuronalactivity
through multiple overlapping mecha-
nisms. Thus, there is a strong interaction
between vascular and neurodegenerative
aspects involved in cognitive impairment
in aging. The impact of chronic hypergly-
cemia on cognition has been shown to
reduce brain glucose metabolism (20)
andleadtoendothelialdamageinconcert
with altered insulin signaling (21). How-
ever, besides the well-known effects of
chronic hyperglycemia on cognitive im-
pairment either by direct neuronal dam-
age mediated by advanced glycosylation
end products or by micro- and macrovas-
cularendothelialdamage,anotherimpor-
tant mechanism that has been suggested
is linked to the association between pe-
ripheral hyperinsulinemia and reduced
brain -amyloid clearance by altered ce-
rebral insulin degrading enzyme activity
(21).
There is also growing interest in pre-
venting and treating Alzheimer disease
during a preclinical state, such as MCI
(transitional state between normal cogni-
tionandAlzheimerdisease).Watsonetal.
(12) demonstrated that the insulin sensi-
tizer,rosiglitazone,wasusefulinolderin-
dividuals with NGT and MCI or early
Alzheimer disease for measures of de-
layed memory and selective attention af-
ter 6 months of treatment. Furthermore,
these authors also reported that plasma




there is a progressive decline in plasma
Ab42asAlzheimerdiseaseprogresses,in-
dicating increased brain sequestration of
-amyloid.Unfortunately,ourstudypro-
tocol did not include the measurement of
circulating -amyloid levels, which have
been shown to undergo signiﬁcant
changes during treatment with rosigli-
tazone. Future investigations should
include parameters testing the concen-
trations of circulating -amyloid in older
individuals with diabetes and MCI. The
most important limitation of our study is
the observational design, which only al-
lows for speculation. Indeed, we were
able to identify a speciﬁc group of older
individuals at a signiﬁcantly high risk for
dementia, by limiting our testing to those
with MCI and recent antidiabetes treat-
ment. The literature is lacking data on
cognitive performance variations over
time in older individuals with type 2 dia-
betes and MCI and to the best of our
knowledge only one recent Japanese
study showed that a drug in the same
class, pioglitazone, improved cognition
using the Alzheimer disease assessment
scale and the Wechsler logical memory
learning test in individuals with type 2
diabetes and Alzheimer disease or MCI
(22). However, this was an open-
controlled trial and the risk of biases can-
not be ruled out. Pioglitazone has also
been shown to reduce the risk of stroke,
thus suggesting a protective role on the
cerebral vascular bed (23). Our ﬁndings
support consideration of the use of glita-
zones in older individuals with type 2 di-
abetes and MCI for future double-blind
clinical trials. Furthermore, one may hy-
pothesize that an improvement in insulin
sensitivity seems to have a more impor-
tant role on cognitive performance in
olderindividualswithtype2diabetesand
MCI than in those with NGT and MCI.
Another important limitation was the fact
that we did not compare subjects with di-
abetes and MCI with those with NGT and
MCI. However, recent randomized trials
testing the use of rosiglitazone in individ-
uals with NGT and Alzheimer disease or
MCI were terminated because of a lack of
effect (24–25), thus underlining the fact
that insulin sensitivity alone may not be
crucial for cognition in individuals with
NGT.
In summary, this present study pro-
vides encouraging evidence that insulin
sensitizers,suchasrosiglitazone,notonly
may be important for reaching metabolic
control in type 2 diabetes but may also
protect against cognitive decline. Large
Table 2—Predictors of longitudinal cognitive performance variation over 36 weeks of
follow-up
TMT-B RAVLT
 P value  P value
All participants (n  97)
Time 61.4730 0.134 5.9875 0.001
Age (years) 3.5150 0.004 0.0988 0.012
Group 25.5932 0.002 0.5240 0.048
FPI 38.2203 0.129 0.3998 0.715
Time  FPI 18.0139 0.024 2.2636 0.001
MF/Rosi group (n  32)
Time 70.6536 0.189 0.7851 0.699
Age (years) 1.2301 0.574 0.0315 0.645
FPI 49.0536 0.069 0.4850 0.510
Time  FPI 15.8370 0.064 1.899 0.009
Each model was adjusted for the following covariates: sex, formal education, diabetes duration (years),
depression, FPG, systolic blood pressure, BMI, triglycerides, and A1C.
Rosiglitazone and cognitive performance
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idinediones will determine whether
mechanisms related to improved insulin
resistance play a protective role against
the evolution of dementia in older indi-
viduals with diabetes and MCI.
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